Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 306 participants.
Also called NCT02923193
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 306 participants
- Sponsor
- Registry
-
NCT02923193
-
- Other papers using this trial's data
- Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Randomized Disrupt PAD III Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Germany, New Zealand
- Registry status
- Completed
Technical summary
Registry record NCT02923193. Randomized; single masking; primary purpose treatment. Start 2017-02-22 (actual); primary completion 2020-05-12 (actual). Results posted on 2023-12-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)
- Condition
- Peripheral Arterial Disease
- Intervention (Device)
- Shockwave Lithoplasty® Peripheral Lithoplasty System
- Intervention (Drug)
- Medtronic IN.PACT (DCB)
- Lead sponsor
- Shockwave Medical, Inc.
Record details
- Record id
cardio:ct-nct02923193- Content hash
ff7b68f35df3db2fa7f9120f317fe202ee96c228512603f4733446302d80a4ef